Mast Therapeutics, Inc. (NASDAQ:SVRA) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $24.25.

A number of brokerages have recently commented on SVRA. ValuEngine lowered Mast Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday. Zacks Investment Research lowered Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd. Roth Capital cut their price target on Mast Therapeutics from $40.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, October 31st. Canaccord Genuity upped their price target on Mast Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 30th. Finally, Jefferies Group began coverage on Mast Therapeutics in a report on Friday, September 22nd. They set a “buy” rating and a $20.00 price target for the company.

Shares of Mast Therapeutics (SVRA) traded up $0.54 during mid-day trading on Friday, hitting $13.49. The stock had a trading volume of 124,886 shares, compared to its average volume of 113,809. Mast Therapeutics has a one year low of $4.60 and a one year high of $16.10. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 9.15.

In other news, Director Yuri Pikover bought 50,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The stock was acquired at an average cost of $7.85 per share, for a total transaction of $392,500.00. Following the completion of the purchase, the director now owns 150,000 shares of the company’s stock, valued at approximately $1,177,500. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.93% of the company’s stock.

WARNING: “Mast Therapeutics, Inc. (SVRA) Receives Average Rating of “Buy” from Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/01/mast-therapeutics-inc-svra-receives-average-rating-of-buy-from-analysts.html.

About Mast Therapeutics

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.